Suven Pharmaceuticals Ltd. (SUVENPHAR) AI Stock Analysis

• Market Cap: ₹370.21B
• Dividend Yield: N/A
• Average Volume (3M): 17.81K
• Price to Earnings (P/E): 97.1
• Beta (1Y): 0.76
• Revenue Growth: 62.25%
• EPS Growth: -0.32%
• Country: IN
• Employees: 1,193
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.60
• Shares Outstanding: 382,567,140
• 10 Day Avg. Volume: 36,018
• 30 Day Avg. Volume: 17,810
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,035.00
• Price Target Upside: 13.22% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 64 Neutral
• Price Target: ₹1,035.00 ▲(13.22% Upside)

Suven Pharmaceuticals' overall stock score is driven by strong financial performance and moderate technical indicators. However, the high P/E ratio suggests overvaluation, which could constrain future growth. The absence of dividend yield and lack of recent earnings call data further impact the score.

Suven Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

How the Company Makes Money

Suven Pharmaceuticals Ltd. generates revenue through multiple streams, primarily from its contract research and manufacturing services (CRAMS), which involve producing pharmaceutical intermediates and APIs for other pharmaceutical companies. By leveraging its R&D capabilities, the company also earns income from its proprietary product pipeline, which includes licensing agreements and collaborations with global pharmaceutical firms. Additionally, Suven Pharmaceuticals benefits from strategic partnerships and alliances that enhance its market reach and product offerings, contributing to its financial growth.

Suven Pharmaceuticals Ltd. Financial Statement Overview

Summary

Suven Pharmaceuticals demonstrates strong revenue growth and profitability metrics, supported by a solid balance sheet with low debt levels. However, recent declines in net income and free cash flow growth suggest potential challenges in operational efficiency or market competitiveness.

Income Statement

Suven Pharmaceuticals has shown consistent revenue growth over the years, with a notable increase from 2024 to 2025. The gross profit margin remains strong, indicative of efficient production processes. However, the decline in net income from 2024 to 2025 suggests potential challenges in managing operating expenses or increased competition. The EBITDA margin indicates a stable operational performance despite reduced EBIT margins.

Balance Sheet

The company's balance sheet reflects a solid equity base with relatively low debt levels, as evidenced by the favorable debt-to-equity ratio. Return on Equity (ROE) remains strong, highlighting the company's ability to generate returns from shareholders' investments. The equity ratio indicates a healthy balance between debt and equity financing, providing stability and reducing financial risk.

Cash Flow

Cash flow analysis shows a decline in free cash flow from 2024 to 2025, primarily due to reduced operating cash flow and increased capital expenditures. The operating cash flow to net income ratio suggests efficient cash generation relative to income, though the free cash flow to net income ratio has weakened, indicating less cash available after investment activities.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.48B	11.98B	13.40B	10.51B	12.90B	9.80B
Gross Profit	6.14B	8.92B	7.55B	6.01B	7.35B	5.60B
EBITDA	4.22B	4.34B	6.20B	4.68B	6.74B	4.57B
Net Income	2.79B	2.65B	4.11B	3.00B	4.54B	3.62B
Balance Sheet
Total Assets	0.00	30.32B	19.66B	22.54B	18.30B	14.74B
Cash, Cash Equivalents and Short-Term Investments	6.56B	2.90B	4.87B	8.21B	5.26B	1.88B
Total Debt	0.00	2.79B	703.41M	649.96M	971.27M	1.43B
Total Liabilities	-20.28B	11.91B	2.31B	2.03B	3.02B	2.94B
Stockholders Equity	20.28B	16.97B	17.35B	20.51B	15.27B	11.81B
Cash Flow
Free Cash Flow	0.00	1.32B	1.65B	3.07B	2.55B	2.73B
Operating Cash Flow	0.00	2.88B	4.51B	3.58B	3.30B	3.83B
Investing Cash Flow	0.00	-2.55B	-1.95B	-3.62B	-1.36B	-3.11B
Financing Cash Flow	0.00	33.20M	-2.36B	-138.02M	-1.56B	-765.53M

Suven Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 914.15
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUVENPHAR, the sentiment is Positive. The current price of 914.15 is below the 20-day moving average (MA) of 931.79, below the 50-day MA of 971.93, and below the 200-day MA of 1079.74, indicating a neutral trend. The MACD of 10.80 indicates Negative momentum. The RSI at 57.91 is Neutral, neither overbought nor oversold. The STOCH value of 63.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SUVENPHAR.

Suven Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AJANTPHARM	72 Outperform	320.05B	34.41	24.28%	2.11%	10.92%	9.76%
BIOCON	68 Neutral	472.92B	110.57	4.68%	0.14%	6.80%	-75.66%
SUVENPHAR	64 Neutral	₹370.21B	97.09		―	62.25%	-0.32%
IPCALAB	60 Neutral	332.75B	42.74	10.62%	0.30%	11.49%	35.00%
GLENMARK	54 Neutral	576.25B	76.45	11.83%	0.12%	10.99%	0.00%
LAURUSLABS	54 Neutral	482.33B	94.72	8.01%	0.13%	17.31%	242.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%